A decade of fragment-based drug design: strategic advances and lessons learned.
about
Lost in Translation (LiT): IUPHAR Review 6X-ray crystallography: Assessment and validation of protein-small molecule complexes for drug discovery.Crystal structure of human arginase I complexed with thiosemicarbazide reveals an unusual thiocarbonyl mu-sulfide ligand in the binuclear manganese clusterProtein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor DiscoveryProcess of Fragment-Based Lead Discovery-A Perspective from NMRA Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System TargetsModeling enzyme-ligand binding in drug discoveryFragment screening and HIV therapeuticsBadapple: promiscuity patterns from noisy evidence.The free energy landscape of small molecule unbindingA virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhAStructural genomics of protein phosphatasesCharacterization of Aquifex aeolicus 4-diphosphocytidyl-2C-methyl-d-erythritol kinase - ligand recognition in a template for antimicrobial drug discoveryScaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentOne Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual ScreeningFunction-biased choice of additives for optimization of protein crystallization - the case of the putative thioesterase PA5185 from Pseudomonas aeruginosa PAO1Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibitionFragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitorsFragment-Based Screen against HIV ProteaseBroad Distribution of Energetically Important Contacts across an Extended Protein InterfaceStructure of the HIV-1 Frameshift Site RNA Bound to a Small Molecule Inhibitor of Viral ReplicationFragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiThe Retinal Specific CD147 Ig0 Domain: From Molecular Structure to Biological ActivityA Small-Molecule Probe Induces a Conformation in HIV TAR RNA Capable of Binding Drug-Like FragmentsNovel isoquinolone PDK1 inhibitors discovered through fragment-based lead discoveryDissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein InterfaceFragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexesExperimental and computational active site mapping as a starting point to fragment-based lead discoveryFragment-Based Screening for Inhibitors of PDE4A Using Enthalpy Arrays and X-ray CrystallographyFragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase InhibitorsDe Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding FragmentsExploring the chemical space around 8-mercaptoguanine as a route to new inhibitors of the folate biosynthesis enzyme HPPKStructure-Based Design of Novel Pyrimido[4,5-c]pyridazine Derivatives as Dihydropteroate Synthase Inhibitors with Increased AffinityFragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated ActivationIntegrated biophysical approach to fragment screening and validation for fragment-based lead discoveryIdentifying ligand-binding hot spots in proteins using brominated fragmentsDiscovery of a Potent Inhibitor of Replication Protein A Protein–Protein Interactions Using a Fragment-Linking ApproachThe identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
P2860
Q24289150-9C6658C0-50BE-44ED-A41A-6A5E597D406BQ24632321-9F497B31-299C-4A73-8F0F-0E3C7C2BDE07Q24650780-483DBED2-7049-4B24-937B-B62DEF780E26Q26738763-A833A705-FBF7-4963-B9A6-EF9C2B765EA8Q26738768-0F8B0D9B-EC0A-4CF4-8145-1A798A888043Q26781471-3FBC413A-7604-4BF2-8A40-2632D5D39903Q26784325-FE459495-3816-4509-9C10-5F8E0226CDDEQ26826945-E4DCBD4D-7A0D-4BEB-B85C-6B0CDF0307B8Q27321430-54CCD04D-6B90-45B8-8946-AAEAAA83ADD2Q27333830-C7FEE071-320F-4809-9781-DC5DC22D6D2CQ27339306-5DCFB02C-C23D-4546-8F56-F3DD6744AED7Q27649211-E185E616-0037-4D79-B0EE-34AE3A809E93Q27650391-076396AC-FB59-4CA0-9F1E-3AD8B426D59DQ27653305-225D0CD3-EEE6-4A20-86A6-8DFCD57DC98BQ27655956-50BCF746-E7F6-4CBC-AB5E-97A6FECDA12BQ27658101-330A20B4-F2F3-460A-9DFE-C3D1CFD8ED55Q27660547-1C613A6B-6ADF-491B-A812-789E81229E79Q27663569-D6BB5448-561E-42DD-880C-14A340CA828AQ27663595-029A286D-4AD8-4CC9-A19D-40973BD3D1BFQ27666255-4A1DADEB-7BF4-4A75-99B6-0AB643F37340Q27666265-51FDF787-9B27-40F6-86AF-1A8A79F98B06Q27666603-28A555E5-AC10-402F-9513-8371449CFA6DQ27667103-177604AB-5B8C-4B86-B2E3-87CA7FEDD9E5Q27668068-9AB0BE90-CFC7-4C16-A52B-2F08FA2A8CD5Q27670818-06C72DC2-712A-4D57-ACDD-900892D32BD0Q27670945-2817B6AF-A276-4F18-8D75-A9A3E481CEF9Q27674729-77CF6BF5-4C5A-4AD4-AD08-228A7D0D1FC3Q27676351-98D939C5-8342-424D-9175-B5F7E9C4143CQ27676521-48547428-2AC8-49D7-A408-A956EBEDFC67Q27676592-9A182048-896E-4831-BF72-4BB16CE5D4A0Q27676858-4CA15D90-4C29-41F9-B238-16E8C19BE9BAQ27677088-9A3CF5B9-3116-43FA-BBB1-B9DD3FACCD19Q27677246-73187254-98D2-424C-8691-19EBD4636329Q27678040-9F23BDE5-2A4F-4965-8555-27C6440806D8Q27678684-5A420EEF-6750-438E-BF11-248BF02FD250Q27678948-B9DCA6BA-3D21-4A2E-86D9-4FE5E02429A5Q27679154-BDF3640B-B713-46A1-AC83-F84D4FDC80EFQ27679833-99A5C0C0-0D79-458F-86AD-9173E10DE75BQ27680422-6E5D73A5-D776-44BA-99DA-17B480A2BE85Q27682055-E5557888-ED5F-4350-9891-EC2C745B7D1E
P2860
A decade of fragment-based drug design: strategic advances and lessons learned.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A decade of fragment-based drug design: strategic advances and lessons learned.
@ast
A decade of fragment-based drug design: strategic advances and lessons learned.
@en
type
label
A decade of fragment-based drug design: strategic advances and lessons learned.
@ast
A decade of fragment-based drug design: strategic advances and lessons learned.
@en
prefLabel
A decade of fragment-based drug design: strategic advances and lessons learned.
@ast
A decade of fragment-based drug design: strategic advances and lessons learned.
@en
P2860
P356
P1476
A decade of fragment-based drug design: strategic advances and lessons learned.
@en
P2093
Jonathan Greer
Philip J Hajduk
P2860
P2888
P304
P356
10.1038/NRD2220
P577
2007-02-09T00:00:00Z
P5875
P6179
1005382535